Stay tuned for a “tweetorial” by @ollidufva, @DrSGandalf and colleagues for more details on main findings and key implications of this @ImmunityCP paper! @DanaFarber @hruh_research @iCAN_Finland @CellPressNews #mmsm #leukemia #lymphoma

Research in Mustjoki Lab @hruh_research was carried out under the iCAN Digital Precision Cancer Medicine Flagship (@iCAN_Finland) & also supported by Research Council of Finland (@SuomenAkatemia), @Syopasaatio, Jane & Aatos Erkko Foundation, and @SigridJuselius

We are grateful at the @CMitsiadesLab for our funding sources that supported this study, including @NIHfunding, @theNCI, @LLSusa, @Ludwig_Cancer at Harvard, @VdeGunzburg, @SU2C, @Myeloma_Society, @LLslf, the Corman Family and Cobb Family

This study provides a comprehensive landscape of molecular changes in NK and blood cancer cells when they interact and the mechanisms contributing to sensitivity vs #resistance to #NKcell-based therapies, providing a framework for new personalized therapies @ImmunityCP #ASH23

Congratulations to @ollidufva & @DrSGandalf, who are co-first authors of this study at @ImmunityCP @CellPressNews. Many thanks to all colleagues & collaborators in this study

New collaborative paper by Mustjoki Lab (@hruh_research) & @CMitsiadesLab published @ImmunityCP. https://t.co/HaE1sH6fnE Single-cell functional genomics of #NKcell #resistance in blood cancers #immunotherapy #myeloma #mmsm #leukemia #lymphoma #CRISPR @DanaFarber @broadinstitute

Very proud to share latest work from Constantine Mitsiades lab, started during my time at @DanaFarber / @harvardmed . https://t.co/FnP9COeNSB

A new study published in @NatureCancer led by @CMitsiadesLab at @danafarber uses CRISPR to identify more than 100 genes as potential leads for the discovery of new drugs for multiple myeloma. Full release ➡️ https://t.co/jSpQTFKWVQ #mmsm #myeloma #CRISPR

Stay tuned for a “tweetorial” describing the main findings and key implications of the study!

Many thanks to all coauthors from @DanaFarber, @broadinstitute, @harvardmed, @WinshipAtEmory, @ufhealthcancer, @theMMRF (@AuclairDan, @joanbethlevy), @MedicineAtUL (@AedinCulhane), @TGen (@PedalheadPHX), @CancerCenterAms (Richard Groen)

Our lab and collaborators completed a preclinical research study in which we used CRISPR to identify which genes have critical functions for multiple myeloma cells and could be promising therapeutic targets with preferential importance for this disease.

Congratulations to @CMitsiadesLab members (Ricardo de Matos Simoes, Ryosuke Shirasaki, Sondra Downey-Kopyscinski, @GeoffMMatthews) and our collaborator @BioBenBarwick, who are co-first authors of this study.

Wonderful collaboration with @CancerDepMap, @DrFranVazquez, @aviadt and many colleagues from @DanaFarber, @broadinstitute, @WinshipAtEmory (Larry Boise), @ufhealthcancer (@jdlicht), and other institutions.

New paper by our lab & collaborators published in @NatureCancer Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias https://t.co/OeGOXI0j5e #mmsm #myeloma #CRISPR @DanaFarber @broadinstitute

Time to wake up the potential of NK-directed therapy in #myeloma. @DrSGandalf showing compelling data to pique our interest. #IMS2022 #IMS

Excited to share our new work on NK cells. Fantastic work by @ollidufva & @DrSGandalf, team members from our lab @HelsinkiUniMed & @CMitsiadesLab @DanaFarberNews and many collaborators. Fascinating to see how different cancer cells impact NK cell responses

We finally tested how knocking out CRISPR hits in cancer cells influences NK cells. This gave some interesting results, such as defective activation with CD58 knockout and increased activation with JAK1 knockout. 18/

Many perturbations had strong transcriptomic effects as seen from the UMAPs. Several of them also affected the IFNy negative feedback response to NK attack, giving clues to how they mediate NK resistance/sensitivity. Also many more interesting downstream effects in the paper 17/

We analyzed the transcriptomic effects of knocking out or activating 65 hits in cancer cells both in the resting state and under NK attack. 16/

We wondered which of the CRISPR hits could explain variation and correlate with sensitivity to NK cells across the PRISM cell lines in their expression levels. Turns out these include activating receptor ligands (NCR3LG1, ULBP1, PVR) and MHC-I. 13/